Cantor Fitzgerald raised the firm’s price target on MiMedx (MDXG) to $12 from $11 and keeps an Overweight rating on the shares following the company reporting a Q2 revenue beat and raising 2025 revenue guidance. Given the firm’s belief that MiMedx and Organogenesis (ORGO) are positioned to take market share in 2026 and represent undervalued opportunities, it would be buyers amid the share’s strength.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDXG: